SCHEMBL2025652

SCHEMBL2025652

CS(=O)(=O)c1ccc(/C(=C\C2CC(F)C(F)C2)C(=O)Nc2ccon2)cc1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.48
HTT P42858 3/20 0.41
ALDH1A1 P00352 3/20 0.36
EPHX2 P34913 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
KDM4E B2RXH2 1/20 0.35
AKR1C3 P42330 2/20 0.34
PTGS2 P35354 2/20 0.34
AKR1C2 P52895 1/20 0.34
AKR1C1 Q04828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2025651 1.00 GCK (0.48) GCKHTTALDH1A1EPHX2SMN1; SMN2
SCHEMBL2020266 0.88 GCK (0.40) GCKHTTALDH1A1EPHX2SMN1; SMN2
SCHEMBL2020269 0.88 GCK (0.40) GCKHTTALDH1A1EPHX2SMN1; SMN2
SCHEMBL2019074 0.83 GCK (0.47) GCKKDM4EAKR1C3PTGS2AKR1C2
SCHEMBL2019078 0.83 GCK (0.47) GCKKDM4EAKR1C3PTGS2AKR1C2
SCHEMBL2022862 0.82 GCK (0.48) GCKALDH1A1RAB9ANPC1KMT2A
SCHEMBL2022021 0.82 GCK (0.50) GCKHTTALDH1A1SMN1; SMN2RAB9A
SCHEMBL2022861 0.82 GCK (0.48) GCKALDH1A1RAB9ANPC1KMT2A
SCHEMBL2022019 0.82 GCK (0.50) GCKHTTALDH1A1SMN1; SMN2RAB9A
SCHEMBL2020451 0.81 GCK (0.45) GCKHTTALDH1A1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2275414-B1 CYCLOPENTYLACRYLAMIDE DERIVATIVE KYORIN SEIYAKU KK (JP) 2015-06-10 EP claimed
US-20110160211-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2011-06-30 US claimed
US-9452977-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2016-09-27 US disclosed
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2015-04-16 US disclosed
US-8946440-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2015-02-03 US disclosed
US-20110160211-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160211-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE GPR119, SLC5A1, SLC5A2 GCK 188/4885HTT 2786/4885ALDH1A1 606/4885
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE GPR119, SLC5A1, SLC5A2 GCK 188/4885HTT 2786/4885ALDH1A1 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.